Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
Article
Oztan, A, Fischer, S, Schrock, AB et al. (2017). Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
. 111 84-87. 10.1016/j.lungcan.2017.07.002
Oztan, A, Fischer, S, Schrock, AB et al. (2017). Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
. 111 84-87. 10.1016/j.lungcan.2017.07.002
Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined. The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment. This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.
